BNT23001

BNT23001 is a proprietary sublingual thin-film formulation of cladribine developed by BioNxt Solutions for the treatment of multiple sclerosis (MS). This innovative oral dissolvable film (ODF) is designed to address challenges faced by MS patients, particularly those with swallowing difficulties, by providing a convenient and patient-friendly alternative to traditional oral tablets. The sublingual delivery system allows for rapid absorption directly into the bloodstream, bypassing the gastrointestinal tract and first-pass liver metabolism. This results in faster onset of action and improved bioavailability compared to standard tablet formulations. Preclinical studies have demonstrated that BNT23001 achieves high absorption rates and pharmacokinetic bioequivalence to Mavenclad (the original cladribine tablet), with no observed toxicity or adverse local effects. The product aims to enhance patient compliance, offer portability, and improve overall treatment experience for people living with MS[1][2][3][5][6][7].